Transactional Content Management

PRODUCTS

  • Our dermatology studies provide results that are more than skin deep. Because the skin is the largest and most easily accessible organ, our dermatology research also facilitates drug development in other areas, including immunology and endocrinology. In addition, we are engaged in studying ways to improve wound healing.

  • The dB-8059 is a wideband Gallium Nitride (GaN) Solid State Power Amplifier (SSPA) engineered for high-power performance across a broad frequency range of 2.0 to 18.0 GHz.

  • As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.

  • Neither traditional nor hybrid clinical trials can operate on rigid EDC systems.

    They require flexible data collection systems that support protocol amendments without downtime and accept mobile data without hassle. As a cloud-native solution, TrialKit bends to accommodate mid-study changes. And as the first full-featured EDC platform available as a native mobile app, TrialKit flexes to meet the demands of traditional, hybrid/decentralized, and completely remote clinical trials.

    Give your team the freedom to build, deploy, and manage their studies, their way—weeks faster than with rigid EDCs and for a fraction of the cost of the major players.

  • Altasciences specializes in lead optimization studies, helping you identify the most promising drug candidates through precise, data-driven preclinical screening. Our expert scientists tailor each study to your unique needs, utilizing efficient non-GLP screening protocols to accelerate decision-making. With streamlined study designs, clear data visualization, and rapid turnaround times, we provide actionable insights to advance your drug discovery pipeline.

WHITE PAPERS AND CASE STUDIES

NEWS